{"id":"NCT02935699","sponsor":"JDP Therapeutics, Inc.","briefTitle":"Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria","officialTitle":"A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-01","primaryCompletion":"2018-04-30","completion":"2018-04-30","firstPosted":"2016-10-17","resultsPosted":"2019-11-27","lastUpdate":"2019-11-27"},"enrollment":262,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Urticaria"],"interventions":[{"type":"DRUG","name":"Test Drug (JDP-205)","otherNames":["QUZYTTIR"]},{"type":"DRUG","name":"Active Control (Diphenhydramine)","otherNames":["Benadryl"]}],"arms":[{"label":"Test Drug","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.","primaryOutcome":{"measure":"Change of Patient Rated Pruritus Score","timeFrame":"2 hr","effectByArm":[{"arm":"Test Drug","deltaMin":-1.61,"sd":0.944},{"arm":"Control","deltaMin":-1.5,"sd":0.984}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States","Canada"]},"refs":{"pmids":["32653333"],"seeAlso":["http://jdptherapeutics.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":127},"commonTop":["Dizziness","Nausea","Burning sensation","Dysgeusia","Headache"]}}